Impact of public health strategies on the birth prevalence of cystic fibrosis in Brittany, France

被引:22
作者
Scotet, V
Audrézet, MP
Roussey, M
Rault, G
Blayau, M
De Braekeleer, M
Férec, C
机构
[1] Hosp Univ, EFS Bretagne, Lab Genet Mol & Histocompatibil, INSERM EMI 01 15, F-29275 Brest, France
[2] CHRU, Hop Sud, Rennes, France
[3] Ctr Perharidy, Roscoff, France
[4] Mol Genet Lab, Rennes, France
[5] Lab Cytogenet, Brest, France
[6] Inst Natl Etud Demog, Paris, France
关键词
D O I
10.1007/s00439-003-0962-0
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Taking into account the situation of Brittany, a region of western France where cystic fibrosis (CF) is common and where a neonatal screening program was set up 14 years ago, the aim of this study was to determine the way in which the birth prevalence of CF has been influenced by the various public health strategies implemented in the region (neonatal screening, prenatal diagnosis, ultrasound examination and family testing). This study used the results of the neonatal screening program, which enabled a precise measure of the prevalence of CF at birth to be obtained. Over the same period, we collected data from prenatal diagnoses carried out in the region, first in families related to a CF child and also those made following the detection of an echogenic bowel upon routine ultrasound examination performed during pregnancy. The prevalence of CF at birth was estimated to be 1/2838 in the region over a 10-year period (1992-2001). By including the 54 CF-affected pregnancies that were terminated during these 10 years, the corrected birth prevalence of CF was 1/1972. Prenatal diagnosis was therefore responsible for a global decrease in CF prevalence at birth of 30.5%. This work constitutes the first study able to provide a precise measure of CF birth prevalence and of its evolution through the combined effects of neonatal screening, prenatal diagnosis, ultrasound examination and family testing.
引用
收藏
页码:280 / 285
页数:6
相关论文
共 31 条
[21]   The HUGO Gene Nomenclature Committee (HGNC) [J].
Povey, S ;
Lovering, R ;
Bruford, E ;
Wright, M ;
Lush, M ;
Wain, H .
HUMAN GENETICS, 2001, 109 (06) :678-680
[22]  
RIORDAN JR, 1989, SCIENCE, V245, P1066
[23]   IDENTIFICATION OF THE CYSTIC-FIBROSIS GENE - CHROMOSOME WALKING AND JUMPING [J].
ROMMENS, JM ;
IANNUZZI, MC ;
KEREM, BS ;
DRUMM, ML ;
MELMER, G ;
DEAN, M ;
ROZMAHEL, R ;
COLE, JL ;
KENNEDY, D ;
HIDAKA, N ;
ZSIGA, M ;
BUCHWALD, M ;
RIORDAN, JR ;
TSUI, LC ;
COLLINS, FS .
SCIENCE, 1989, 245 (4922) :1059-1065
[24]   Neonatal screening for cystic fibrosis in Brittany, France:: assessment of 10 years' experience and impact on prenatal diagnosis [J].
Scotet, V ;
de Braekeleer, M ;
Roussey, M ;
Rault, G ;
Parent, P ;
Dagorne, M ;
Journel, H ;
Lemoigne, A ;
Codet, JP ;
Catheline, M ;
David, V ;
Chaventré, A ;
Duguépéroux, I ;
Verlingue, C ;
Quéré, I ;
Mercier, B ;
Audrézet, MP ;
Férec, C .
LANCET, 2000, 356 (9232) :789-794
[25]   Prenatal detection of cystic fibrosis by ultrasonography:: a retrospective study of more than 346 000 pregnancies [J].
Scotet, V ;
De Braekeleer, M ;
Audrézet, MP ;
Quéré, I ;
Mercier, B ;
Duguépéroux, I ;
Andrieux, J ;
Blayau, M ;
Férec, C .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (06) :443-448
[26]   Spatial and temporal distribution of cystic fibrosis and of its mutations in Brittany, France:: a retrospective study from 1960 [J].
Scotet, V ;
Gillet, D ;
Duguépéroux, I ;
Audrézet, MP ;
Bellis, G ;
Garnier, B ;
Roussey, M ;
Rault, G ;
Parent, P ;
De Braekeleer, M ;
Férec, C .
HUMAN GENETICS, 2002, 111 (03) :247-254
[27]  
TSUI LC, 2003, CYSTIC FIBROSIS MUTA
[28]   Neonatal screening for cystic fibrosis [J].
Wald, NJ ;
Morris, JK .
BRITISH MEDICAL JOURNAL, 1998, 316 (7129) :404-405
[29]   Clinical outcomes of newborn screening for cystic fibrosis [J].
Waters, DL ;
Wilcken, B ;
Irwig, L ;
Van Asperen, P ;
Mellis, C ;
Simpson, JM ;
Brown, J ;
Gaskin, KJ .
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION, 1999, 80 (01) :F1-F7
[30]  
Welsh MJ., 2001, METABOLIC MOL BASES, V3, P5121, DOI DOI 10.1036/OMMBID.236